JPWO2020154189A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020154189A5 JPWO2020154189A5 JP2021541607A JP2021541607A JPWO2020154189A5 JP WO2020154189 A5 JPWO2020154189 A5 JP WO2020154189A5 JP 2021541607 A JP2021541607 A JP 2021541607A JP 2021541607 A JP2021541607 A JP 2021541607A JP WO2020154189 A5 JPWO2020154189 A5 JP WO2020154189A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- subject
- seq
- solid tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims description 42
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 34
- DRTQHJPVMGBUCF-UCVXFZOQSA-N Uridine Natural products O[C@H]1[C@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UCVXFZOQSA-N 0.000 claims description 24
- 239000002777 nucleoside Substances 0.000 claims description 9
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 9
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 claims description 8
- 229940045145 Uridine Drugs 0.000 claims description 8
- DWRXFEITVBNRMK-JXOAFFINSA-N 5-Methyluridine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 claims description 5
- PTJWIQPHWPFNBW-GBNDHIKLSA-N Pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims 47
- 239000008194 pharmaceutical composition Substances 0.000 claims 39
- 201000011510 cancer Diseases 0.000 claims 35
- 238000002560 therapeutic procedure Methods 0.000 claims 22
- 102000004169 proteins and genes Human genes 0.000 claims 12
- 108090000623 proteins and genes Proteins 0.000 claims 12
- 206010025650 Malignant melanoma Diseases 0.000 claims 9
- 201000001441 melanoma Diseases 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 238000003782 apoptosis assay Methods 0.000 claims 8
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims 7
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 7
- 238000002347 injection Methods 0.000 claims 7
- 239000007924 injection Substances 0.000 claims 7
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 108090001123 antibodies Proteins 0.000 claims 5
- 102000004965 antibodies Human genes 0.000 claims 5
- 102100006400 CSF2 Human genes 0.000 claims 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 4
- 108009000344 Head and Neck Squamous Cell Carcinoma Proteins 0.000 claims 4
- 102000006992 Interferon-alpha Human genes 0.000 claims 4
- 108010047761 Interferon-alpha Proteins 0.000 claims 4
- 206010027476 Metastasis Diseases 0.000 claims 4
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 4
- 210000004027 cells Anatomy 0.000 claims 4
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 4
- 230000002601 intratumoral Effects 0.000 claims 4
- 230000003902 lesions Effects 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 102100007290 CD274 Human genes 0.000 claims 3
- 101710012053 CD274 Proteins 0.000 claims 3
- 229920001320 Leader sequence (mRNA) Polymers 0.000 claims 3
- 230000027455 binding Effects 0.000 claims 3
- 231100000221 frame shift mutation induction Toxicity 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 238000007920 subcutaneous administration Methods 0.000 claims 3
- 208000001446 Anaplastic Thyroid Carcinoma Diseases 0.000 claims 2
- 206010002240 Anaplastic thyroid cancer Diseases 0.000 claims 2
- 210000001072 Colon Anatomy 0.000 claims 2
- 206010010356 Congenital anomaly Diseases 0.000 claims 2
- 210000004072 Lung Anatomy 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010061289 Metastatic neoplasm Diseases 0.000 claims 2
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 2
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 2
- 206010025310 Other lymphomas Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 230000001394 metastastic Effects 0.000 claims 2
- 201000003731 mucosal melanoma Diseases 0.000 claims 2
- 208000009956 Adenocarcinoma Diseases 0.000 claims 1
- 210000000481 Breast Anatomy 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010019695 Hepatic neoplasm Diseases 0.000 claims 1
- 206010020243 Hodgkin's disease Diseases 0.000 claims 1
- 201000006743 Hodgkin's lymphoma Diseases 0.000 claims 1
- 102000004556 Interleukin-15 Receptors Human genes 0.000 claims 1
- 108010017535 Interleukin-15 Receptors Proteins 0.000 claims 1
- 210000003734 Kidney Anatomy 0.000 claims 1
- 210000004185 Liver Anatomy 0.000 claims 1
- 210000001165 Lymph Nodes Anatomy 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 108010019706 Nivolumab Proteins 0.000 claims 1
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims 1
- 229950010773 Pidilizumab Drugs 0.000 claims 1
- 210000002307 Prostate Anatomy 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 210000003491 Skin Anatomy 0.000 claims 1
- 229920000401 Three prime untranslated region Polymers 0.000 claims 1
- 208000009955 Thyroid Neoplasms Diseases 0.000 claims 1
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims 1
- 201000009030 carcinoma Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000002496 gastric Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 239000006193 liquid solution Substances 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 108010026276 pembrolizumab Proteins 0.000 claims 1
- 108010051812 pidilizumab Proteins 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000000268 renotropic Effects 0.000 claims 1
- 201000000582 retinoblastoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000005969 uveal melanoma Diseases 0.000 claims 1
- 125000003835 nucleoside group Chemical group 0.000 description 6
- 150000007523 nucleic acids Chemical group 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 1
Description
一部の実施形態では、RNAの投与は、GM-CSFをコードするRNAを投与すること、ならびにIL-12sc、IFNα、およびIL-15スシをコードするRNAをさらに投与することを含む。 In some embodiments, administering RNA comprises administering RNA encoding GM-CSF and further administering RNA encoding IL-12sc, IFNα, and IL-15 sushi.
一部の実施形態では、進行期、切除不能、または転移性固形腫瘍がんを治療するための方法であって、GM-CSFをコードするRNAを投与すること、ならびにIL-12sc、IFNα、およびIL-15スシをコードするRNAをさらに投与すること、ならびに抗PD-1抗体をさらに投与することを含む方法が包含される。 In some embodiments, a method for treating advanced, unresectable, or metastatic solid tumor cancer comprising administering RNA encoding GM-CSF and IL-12sc, IFNα, and Methods comprising further administering RNA encoding IL-15 sushi and further administering an anti-PD-1 antibody are encompassed.
実施例1.2B. 注射しようとする病変
すべての用量レベル(DL1~DL8)は、表5に提供されている病変サイズに関する指針に従う。参加者は、固形腫瘍効果判定基準(RECIST1.1)基準(選択基準I
05を参照)による標的病変として最低で1つの測定可能な病変を有し、注射および腫瘍生検のための最低で1つまたはそれ以上の皮膚病変/皮下病変を有する。参加者は、基線時の1つの病変の生検、ならびに初回投与の5週目~8週目の治療中評価としての1つの病変の生検を考慮して、その所与の用量レベル(表7)の注射容積に十分でなければならない腫瘍病変のサイズに基づいて選択する。
Example 1.2B. Lesions to be Injected All dose levels (DL1-DL8) follow the lesion size guidelines provided in Table 5. Participants were asked to complete the Solid Tumor Response Criteria (RECIST 1.1) criteria (selection criterion I
05) and a minimum of 1 or more cutaneous/subcutaneous lesions for injection and tumor biopsy. Participants will be assigned to their given dose level (Table 7) Select based on the size of the tumor lesion, which should be sufficient for the injection volume.
Claims (37)
(ii)対象は、(a)抗PD-1療法に対して後天的抵抗性、(b)抗PD-L1療法に対して後天的抵抗性、もしくは(c)(a)および(b)の両方、を有する固形腫瘍がんを有する;または
(iii)対象は、(a)抗PD-1療法に対して先天的抵抗性、(b)抗PD-L1療法に対して先天的抵抗性、もしくは(c)(a)および(b)の両方、を有する固形腫瘍がんを有する;または
(iv)対象は、進行期、切除不能、もしくは転移性固形腫瘍がんを有する;または(v)不応性もしくは抵抗性がんは、指定の治療に応答しないがんである;または
(vi)不応性は、治療のまさに最初から生じる;または
(vii)不応性は、治療中に生じる;または
(viii)がんは、治療が始まる前に抵抗性である;または
(ix)対象は、(a)抗プログラム細胞死1(PD-1)療法に応答しない、(b)抗プログラム細胞死1リガンド1(PD-L1)療法に応答しない、もしくは(c)(a)および(b)の両方の、がんを有する;または
(x)対象は、指定の治療に不応性もしくは抵抗性になりつつあるがんを有し、該指定の治療は、抗PD-1もしくは抗PD-L1療法としてである;または
(xi)対象は、療法を最初に受けて以来、該療法に対する応答性が低下している;または
(xii)対象は、療法を受けたことがないが、典型的には該療法に応答しないタイプのがんを有する、
請求項1に記載の医薬組成物。 (i) the subject has (a) anti-PD-1-resistant solid tumor cancer, (b) anti-PD-L1-resistant solid tumor cancer, or (c) both (a) and (b) or (ii) the subject is (a) acquired resistance to anti-PD-1 therapy, (b) acquired resistance to anti-PD-L1 therapy, or (c) (a) and (b) or (iii) the subject has (a) congenital resistance to anti-PD-1 therapy, (b) congenital resistance to anti-PD-L1 therapy or (c) both (a) and (b); or (iv) the subject has advanced stage, unresectable, or metastatic solid tumor cancer; or ( v) a refractory or resistant cancer is a cancer that does not respond to a given treatment; or (vi) refractory occurs from the very beginning of treatment; or (vii) refractory occurs during treatment; or (viii) the cancer is refractory before treatment begins; or (ix) the subject is (a) unresponsive to anti-programmed cell death 1 (PD-1) therapy, (b) anti-programmed cell death 1 unresponsive to ligand 1 (PD-L1) therapy, or (c) has cancer in both (a) and (b); or (x) the subject becomes refractory or resistant to the indicated therapy has developing cancer and the indicated treatment is as anti-PD-1 or anti-PD-L1 therapy; or (xi) the subject has become less responsive to the therapy since it was first received or (xii) the subject has never received therapy, but has a type of cancer that typically does not respond to said therapy.
A pharmaceutical composition according to claim 1 .
(i)対象はヒトである;
(ii)対象は、転移性固形腫瘍を有する;
(iii)対象は、切除不能な固形腫瘍を有する;
(iv)対象は、以前に抗PD-1もしくは抗PD-L1療法で治療されたことがない;
(v)対象は、他の治療選択肢を有していない;
(vi)対象は、2つまたは3つの腫瘍病変を有する;
(vii)対象は、固形腫瘍効果判定基準(RECIST)1.1基準に従って測定可能な疾患を有する;
(viii)対象は、3か月よりも長い平均余命を有する;または
(ix)対象は、少なくとも18歳である、
の1つまたはそれ以上を充たしている、請求項1~3のいずれか1項に記載の医薬組成物。 (i) to (viii) below:
(i) the subject is human;
(ii) the subject has a metastatic solid tumor;
(iii) the subject has an unresectable solid tumor;
(iv) the subject has not been previously treated with anti-PD-1 or anti-PD-L1 therapy;
(v) the subject has no other treatment options;
(vi) the subject has 2 or 3 tumor lesions;
(vii) the subject has measurable disease according to the Solid Tumor Efficacy Criteria (RECIST) 1.1 criteria;
(viii) the subject has a life expectancy greater than 3 months; or (ix) the subject is at least 18 years old.
The pharmaceutical composition according to any one of claims 1 to 3, which is filled with one or more of
(i)フレームシフト突然変異は、B2Mのエクソン1に存在する;または
(ii)フレームシフト突然変異は、p.Leu13fs、p.Ser14fs、もしくはp.Leu13fsおよびp.Ser14fsの両方、を含む、
の1つまたはそれ以上が満たされる、請求項9に記載の医薬組成物。 (i) to (ii) below:
(i) the frameshift mutation is in exon 1 of B2M; or (ii) the frameshift mutation is p. Leu13fs, p. Ser14fs, or p. Leu13fs and p. Both of Ser14fs, including
10. The pharmaceutical composition according to claim 9, wherein one or more of
(1)対象は、B2M機能の部分的もしくは完全な喪失を有しない対象と比較して、低減されたレベルのB2Mタンパク質を有する;または
(ii)対象は、対照と比較して低減されたレベルの表面発現主要組織適合遺伝子複合体クラスI(MHC I)を有し、場合により、該対照は、同じ対象に由来する非がん性サンプルである、
の1つまたはそれ以上が満たされる、請求項5~10のいずれか1項に記載の医薬組成物。 (i) to (ii) below:
(1) the subject has reduced levels of B2M protein compared to a subject without partial or complete loss of B2M function; or (ii) the subject has reduced levels compared to a control and optionally the control is a non-cancerous sample from the same subject.
The pharmaceutical composition according to any one of claims 5 to 10, wherein one or more of
(ii)固形腫瘍がんは、ブドウ膜黒色腫もしく粘膜黒色腫である;または
(iii)固形腫瘍がんは、(a)腫瘍内注射に適した表在性転移、(b)腫瘍内注射に適した皮下転移、(c)腫瘍内注射に適したリンパ節転移、もしくは(d)(a)~(c)のいずれかの組み合わせ、を含む黒色腫である;または
(iv)固形腫瘍がんは、(a)粘膜部位のみを有するHNSCC、(b)粘膜部位のみを有する粘膜黒色腫、もしくは(c)(a)および(b)の両方、である、
請求項1~14のいずれか1項に記載の医薬組成物。 (i) the solid tumor cancer is melanoma; or (ii) the solid tumor cancer is uveal melanoma or mucosal melanoma; or (iii) the solid tumor cancer is (a) a tumor (b) subcutaneous metastasis suitable for intratumoral injection; (c) lymph node metastasis suitable for intratumoral injection; or (d) any of (a)-(c) or (iv) the solid tumor cancer is (a) HNSCC with only a mucosal site, (b) mucosal melanoma with only a mucosal site, or (c) (a) and ( b) both of
The pharmaceutical composition according to any one of claims 1-14.
医薬組成物。 17. The pharmaceutical composition of any one of claims 1-16, wherein the subject has more than one solid tumor.
(i)固形腫瘍がんは、ステージIII、ステージIIIのサブセット、ステージIV、もしくはステージIVのサブセットである;
(ii)固形腫瘍がんは、進行期であり切除不能である;または
(iii)固形腫瘍がんは、対象においてその発生源から対象の別の部位に広がっている、
の1つまたはそれ以上が満たされる、請求項1~19のいずれか1項に記載の医薬組成物。 (i) to (iii) below:
(i) the solid tumor cancer is stage III, a subset of stage III, stage IV, or a subset of stage IV;
(ii) the solid tumor cancer is advanced stage and unresectable; or (iii) the solid tumor cancer has spread in the subject from its source to another site in the subject.
A pharmaceutical composition according to any one of claims 1 to 19, wherein one or more of
(i)固形腫瘍がんは、1つまたはそれ以上の皮膚病変もしくは皮下病変を有し、場合により、該がんは皮膚がんではない;
(ii)固形腫瘍がんは、ステージIIIB、ステージIIIC、もしくはステージIVの黒色腫である;
(iii)固形腫瘍がんは、抗PD-1もしくは抗PD-L1療法も常用的に使用されない固形腫瘍がんである;
(iv)固形腫瘍がんは、黒色腫でもなく、非小細胞肺がんでもなく、腎臓がんでもなく、頭頸部がんでもなく、乳がんでもなく、CSCCでもない;
(v)固形腫瘍がんは、抗PD1もしくは抗PD-L1療法が常用的に使用される固形腫瘍がんであるが、該療法でまだ治療されていない;
(vi)固形腫瘍がんは、(a)抗PD-1もしくは抗PD-L1療法に対して抵抗性の、(b)抗PD-1もしくは抗PD-L1療法に対して不応性の、もしくは(c)(a)および(b)の両方の、ステージIIIB、IIIC、もしくは切除不能なステージIVの黒色腫である;または
(vii)固形腫瘍がんは、(a)表在性もしくは皮下の病変、(b)表在性もしくは皮下の転移、もしくは(c)(a)および(b)の両方、を含む、
の1つまたはそれ以上が満たされる、請求項1~20のいずれか1項に記載の医薬組成物。 (i) to (vii) below:
(i) the solid tumor cancer has one or more skin or subcutaneous lesions and optionally the cancer is not skin cancer;
(ii) the solid tumor cancer is stage IIIB, stage IIIC, or stage IV melanoma;
(iii) the solid tumor cancer is a solid tumor cancer for which neither anti-PD-1 nor anti-PD-L1 therapy is routinely used;
(iv) the solid tumor cancer is not melanoma, non-small cell lung cancer, renal cancer, head and neck cancer, breast cancer, or CSCC;
(v) the solid tumor cancer is a solid tumor cancer for which anti-PD1 or anti-PD-L1 therapy is routinely used, but has not yet been treated with such therapy;
(vi) the solid tumor cancer is (a) refractory to anti-PD-1 or anti-PD-L1 therapy, (b) refractory to anti-PD-1 or anti-PD-L1 therapy, or (c) stage IIIB, IIIC, or unresectable stage IV melanoma, both (a) and (b); lesions, (b) superficial or subcutaneous metastases, or (c) both (a) and (b);
A pharmaceutical composition according to any one of claims 1 to 20, wherein one or more of
(ii)抗PD-1療法も抗PD-L1療法も常用的に使用されない;および
(iii)他の好適な治療選択肢がない、
請求項1~21のいずれか1項に記載の医薬組成物。 (i) the solid tumor cancer is not melanoma, CSCC, or HNSCC; and (ii) neither anti-PD-1 nor anti-PD-L1 therapy is routinely used; and (iii) other no suitable treatment options
The pharmaceutical composition according to any one of claims 1-21.
(i)対象は、少なくとも18歳であり;
(ii)対象は、以前の抗PD-1または抗PD-L1療法に失敗しており;
(iii)対象は、最低で2つの病変を有し;および
(iv)黒色腫は、直接腫瘍内注射に適した腫瘍を含む、
前記医薬組成物。 RNA encoding IL-12sc protein, RNA encoding IL-15 sushi protein, IFNα for use in combination with an anti-programmed cell death 1 (PD-1) antibody in the treatment of a subject with advanced melanoma A pharmaceutical composition comprising an RNA encoding a protein and an RNA encoding a GM-CSF protein, wherein:
(i) the subject is at least 18 years old;
(ii) the subject has failed prior anti-PD-1 or anti-PD-L1 therapy;
(iii) the subject has a minimum of 2 lesions; and (iv) the melanoma comprises a tumor suitable for direct intratumoral injection.
Said pharmaceutical composition.
(ii)IL-12scタンパク質は、配列番号14のアミノ酸配列、もしくは配列番号14のアミノ酸配列と少なくとも99%、98%、97%、96%、95%、90%、85%、もしくは80%同一性を有するアミノ酸配列を含む;または
(iii)IL-12scタンパク質をコードするRNAは、IL-12scのp40部分(配列番号17もしくは18のヌクレオチド1~984)と少なくとも99%、98%、97%、96%、95%、90%、85%、もしくは80%同一性、およびIL-12scのp30部分(配列番号17もしくは18のヌクレオチド1027~1623)と少なくとも99%、98%、97%、96%、95%、90%、85%、もしくは80%同一性を有するヌクレオチド配列を含み、該p40部分と該p35部分との間に、リンカーポリペプチドをコードするヌクレオチドをさらに含む;または
(iv)(i)~(iii)のいずれかの組み合わせである、
請求項1~23のいずれか1項に記載の医薬組成物。 (i) the RNA encoding the IL-12sc protein is the nucleotide sequence of SEQ ID NO: 17 or 18, or at least 99%, 98%, 97%, 96%, 95%, 90% of the nucleotide sequence of SEQ ID NO: 17 or 18 , 85%, or 80% identity; or (ii) the IL-12sc protein comprises the amino acid sequence of SEQ ID NO: 14, or at least 99%, 98%, 97% with the amino acid sequence of SEQ ID NO: 14 or (iii) the RNA encoding the IL-12sc protein comprises the p40 portion of IL-12sc (SEQ ID NO: 17 or 18 nucleotides 1-984) and at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the p30 portion of IL-12sc (of SEQ ID NO: 17 or 18) nucleotides 1027-1623), and between said p40 portion and said p35 portion. or (iv) any combination of (i)-(iii).
The pharmaceutical composition according to any one of claims 1-23.
(ii)IL-15スシタンパク質は、配列番号24のアミノ酸配列、もしくは配列番号24のアミノ酸配列と少なくとも99%、98%、97%、96%、95%、90%、85%、もしくは80%同一性を有するアミノ酸配列を含む;または
(iii)IL-15スシタンパク質をコードするRNAは、IL-15受容体アルファのスシドメイン(配列番号26のヌクレオチド1~321)と少なくとも99%、98%、97%、96%、95%、90%、85%、もしくは80%同一性、および成熟IL-15(配列番号26のヌクレオチド382~729)と少なくとも99%、98%、97%、96%、95%、90%、85%、もしくは80%同一性を有するヌクレオチド配列を含み、場合により、該IL-15のスシドメインと該成熟IL-15との間に、リンカーポリペプチドをコードするヌクレオチドをさらに含む;または
(iv)(i)~(iii)のいずれかの組み合わせである、
請求項1~24のいずれか1項に記載の医薬組成物。 (i) RNA encoding IL-15 sushi protein is the nucleotide sequence of SEQ ID NO: 26, or at least 99%, 98%, 97%, 96%, 95%, 90%, 85% of the nucleotide sequence of SEQ ID NO: 26 or (ii) the IL-15 sushi protein comprises the amino acid sequence of SEQ ID NO:24, or at least 99%, 98%, 97%, 96% with the amino acid sequence of SEQ ID NO:24 or (iii) the RNA encoding the IL-15 sushi protein comprises the sushi domain of IL-15 receptor alpha (SEQ ID NO: 26 nucleotides 1-321) and at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identical to mature IL-15 (nucleotides 382-729 of SEQ ID NO:26) ) and optionally the sushi domain of said IL-15 and said mature IL. -15, further comprising a nucleotide encoding a linker polypeptide; or (iv) any combination of (i) to (iii).
The pharmaceutical composition according to any one of claims 1-24.
(ii)IFNαタンパク質は、配列番号19のアミノ酸配列、もしくは配列番号19のアミノ酸配列と少なくとも99%、98%、97%、96%、95%、90%、85%、もしくは80%同一性を有するアミノ酸配列を含む;または
(iii)(i)および(ii)の両方である、
請求項1~25のいずれか1項に記載の医薬組成物。 (i) the RNA encoding the IFNα protein is the nucleotide sequence of SEQ ID NO: 22 or 23, or at least 99%, 98%, 97%, 96%, 95%, 90%, 85% of the nucleotide sequence of SEQ ID NO: 22 or 23 or (ii) the IFNα protein comprises the amino acid sequence of SEQ ID NO: 19 or at least 99%, 98%, 97%, 96% with the amino acid sequence of SEQ ID NO: 19, or (iii) both (i) and (ii),
The pharmaceutical composition according to any one of claims 1-25.
6%、95%、90%、85%、もしくは80%同一性を有するヌクレオチド配列を含む;または
(ii)GM-CSFタンパク質は、配列番号27のアミノ酸配列、もしくは配列番号27のアミノ酸配列と少なくとも99%、98%、97%、96%、95%、90%、85%、もしくは80%同一性を有するアミノ酸配列を含む;または
(iii)(i)および(ii)の両方である、
請求項1~26のいずれか1項に記載の医薬組成物。 (i) the RNA encoding the GM-CSF protein is the nucleotide sequence of SEQ ID NO:29 or at least 99%, 98%, 97%, 9% of the nucleotide sequence of SEQ ID NO:29;
or (ii) the GM-CSF protein comprises the amino acid sequence of SEQ ID NO:27, or at least the amino acid sequence of SEQ ID NO:27 or (iii) both (i) and (ii),
A pharmaceutical composition according to any one of claims 1-26.
(i)少なくとも1つのRNAは、5’キャップm2 7,3’-OGppp(m1 2’-O)ApGもしくは3’-O-Me-m7G(5’)ppp(5’)Gを含む;
(ii)各RNAは、5’キャップm2 7,3’-OGppp(m1 2’-O)ApGもしくは3’-O-Me-m7G(5’)ppp(5’)Gを含む;
(iii)少なくとも1つのRNAは、配列番号4および6からなる群から選択されるヌクレオチド配列、もしくは配列番号4および6からなる群から選択されるヌクレオチド配列と少なくとも99%、98%、97%、96%、95%、90%、85%、もしくは80%同一性を有するヌクレオチド配列を含む5’UTRを含む;
(iv)各RNAは、配列番号4および6からなる群から選択されるヌクレオチド配列、もしくは配列番号4および6からなる群から選択されるヌクレオチド配列と少なくとも99%、98%、97%、96%、95%、90%、85%、もしくは80%同一性を有するヌクレオチド配列を含む5’UTRを含む;
(v)少なくとも1つのRNAは、配列番号8のヌクレオチド配列、もしくは配列番号8のヌクレオチド配列と少なくとも99%、98%、97%、96%、95%、90%、85%、もしくは80%同一性を有するヌクレオチド配列を含む3’UTRを含む;
(vi)各RNAは、配列番号8のヌクレオチド配列、もしくは配列番号8のヌクレオチド配列と少なくとも99%、98%、97%、96%、95%、90%、85%、もしくは80%同一性を有するヌクレオチド配列を含む3’UTRを含む;または
(vii)少なくとも1つのRNAは、ポリAテールを含む、
の1つまたはそれ以上が満たされる、請求項1~29のいずれか1項に記載の医薬組成物。 (i) to (vii) below:
(i) at least one RNA is 5′ capped m 2 7,3′-O Gppp(m 1 2′-O )ApG or 3′-O-Me-m 7 G(5′)ppp(5′) including G;
(ii) each RNA has a 5′ cap m 2 7,3′-O Gppp(m 1 2′-O )ApG or 3′-O-Me-m 7 G(5′)ppp(5′)G; include;
(iii) at least one RNA comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS: 4 and 6, or at least 99%, 98%, 97% with a nucleotide sequence selected from the group consisting of SEQ ID NOS: 4 and 6; including a 5'UTR comprising a nucleotide sequence with 96%, 95%, 90%, 85%, or 80% identity;
(iv) each RNA is at least 99%, 98%, 97%, 96% with a nucleotide sequence selected from the group consisting of SEQ ID NOs: 4 and 6, or a nucleotide sequence selected from the group consisting of SEQ ID NOs: 4 and 6; , a 5'UTR comprising a nucleotide sequence having 95%, 90%, 85%, or 80% identity;
(v) at least one RNA is the nucleotide sequence of SEQ ID NO:8 or at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identical to the nucleotide sequence of SEQ ID NO:8 a 3'UTR containing a nucleotide sequence having a specific identity;
(vi) each RNA is at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identical to the nucleotide sequence of SEQ ID NO:8 or to the nucleotide sequence of SEQ ID NO:8; or (vii) at least one RNA comprises a poly A tail,
A pharmaceutical composition according to any one of claims 1 to 29, wherein one or more of
(i)m2 7,3’-OGppp(m1 2’-O)ApGまたは3’-O-Me-m7G(5’)ppp(5’)Gを含む5’キャップ;
(ii)(a)配列番号4および6からなる群から選択されるヌクレオチド配列、または(b)配列番号4および6からなる群から選択されるヌクレオチド配列と少なくとも99%、98%、97%、96%、95%、90%、85%、もしくは80%同一性を有するヌクレオチド配列を含む5’UTR;
(iii)(a)配列番号8のヌクレオチド配列、または(b)配列番号8のヌクレオチド配列と少なくとも99%、98%、97%、96%、95%、90%、85%、もしくは80%同一性を有するヌクレオチド配列を含む3’UTR;ならびに
(iv)少なくとも100個のヌクレオチドを含むポリAテール、
を含む、請求項1~30のいずれか1項に記載の医薬組成物。 one or more RNAs are
(i) a 5′ cap comprising m 2 7,3′-O Gppp(m 1 2′-O )ApG or 3′-O-Me-m 7 G(5′)ppp(5′)G;
(ii) (a) a nucleotide sequence selected from the group consisting of SEQ ID NOs: 4 and 6, or (b) a nucleotide sequence selected from the group consisting of SEQ ID NOs: 4 and 6 and at least 99%, 98%, 97%; a 5'UTR comprising a nucleotide sequence with 96%, 95%, 90%, 85%, or 80% identity;
(iii) (a) the nucleotide sequence of SEQ ID NO:8, or (b) at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identical to the nucleotide sequence of SEQ ID NO:8 and (iv) a poly A tail comprising at least 100 nucleotides,
The pharmaceutical composition according to any one of claims 1 to 30, comprising
(i)RNAは、同時に投与される;
(ii)RNAは、注射により投与され、該RNAは、注射前に液体溶液中で一緒に混合される;または
(iii)RNAは、ネオアジュバント設定で投与される、
の1つまたはそれ以上が満たされる、請求項1~32のいずれか1項に記載の医薬組成物。 (i) to (iii) below:
(i) the RNA is administered simultaneously;
(ii) the RNA is administered by injection, the RNA being mixed together in a liquid solution prior to injection; or (iii) the RNA being administered in a neoadjuvant setting.
A pharmaceutical composition according to any one of claims 1 to 32, wherein one or more of
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962794896P | 2019-01-21 | 2019-01-21 | |
US62/794,896 | 2019-01-21 | ||
US201962926379P | 2019-10-25 | 2019-10-25 | |
US62/926,379 | 2019-10-25 | ||
EP19306471 | 2019-11-14 | ||
EP19306471.4 | 2019-11-14 | ||
PCT/US2020/014039 WO2020154189A1 (en) | 2019-01-21 | 2020-01-17 | Therapeutic rna and anti-pd1 antibodies for advanced stage solid tumor cancers |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022518236A JP2022518236A (en) | 2022-03-14 |
JPWO2020154189A5 true JPWO2020154189A5 (en) | 2023-02-07 |
Family
ID=69582159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021541607A Pending JP2022518236A (en) | 2019-01-21 | 2020-01-17 | Therapeutic RNA and anti-PD1 antibody for advanced solid tumor cancer |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220288199A1 (en) |
EP (1) | EP3914355A1 (en) |
JP (1) | JP2022518236A (en) |
KR (1) | KR20210118870A (en) |
CN (1) | CN113507963A (en) |
AU (1) | AU2020210614A1 (en) |
BR (1) | BR112021013965A2 (en) |
CA (1) | CA3126110A1 (en) |
IL (1) | IL284645A (en) |
MX (1) | MX2021008605A (en) |
SG (1) | SG11202107396RA (en) |
TW (1) | TW202043274A (en) |
WO (1) | WO2020154189A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6949131B2 (en) | 2017-02-28 | 2021-10-13 | サノフイSanofi | Therapeutic RNA |
TW202043256A (en) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | Prostate neoantigens and their uses |
JP2022518235A (en) * | 2019-01-21 | 2022-03-14 | サノフイ | RNA for the treatment of advanced solid tumor cancer |
IL300975A (en) * | 2020-09-03 | 2023-04-01 | Regeneron Pharma | Methods of treating cancer pain by administering a pd-1 inhibitor |
JP2023550880A (en) * | 2020-10-26 | 2023-12-06 | サイチューン ファーマ | IL-2/IL-15Rβγ agonist for treating non-melanoma skin cancer |
CA3195627A1 (en) * | 2020-10-26 | 2022-05-05 | Stefano FERRARA | Il-2/il-15r.beta..gamma. agonist for treating squamous cell carcinoma |
CA3220882A1 (en) * | 2021-07-02 | 2023-01-05 | David Scott Johnson | Anti-ctla-4 binding proteins and methods of use thereof |
CN115260264B (en) * | 2022-02-28 | 2023-06-09 | 广州市恒诺康医药科技有限公司 | Compounds for RNA capping and uses thereof |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2406760C3 (en) | 2005-05-09 | 2017-11-28 | Оно Фармасьютикал Ко., Лтд. | HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMABLE DEATH 1 PROTECTION (PD-1) AND METHODS OF CANCER TREATMENT USING ANTI-PD-1-ANTI-BODY, INDEPENDENTLY OR IN COMBINATION WITH OTHER IMMUNETURAH AND I And I And I And I, In The Combine, I And I Do Not Allocate To Them, Combined With Other Overarching |
SI2170959T1 (en) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
SI2350129T1 (en) | 2008-08-25 | 2015-11-30 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
RU2625034C2 (en) | 2011-04-20 | 2017-07-11 | МЕДИММЬЮН, ЭлЭлСи | Antibodies and other molecules binding b7-h1 and pd-1 |
US9815897B2 (en) | 2013-05-02 | 2017-11-14 | Anaptysbio, Inc. | Antibodies directed against programmed death-1 (PD-1) |
CN104250302B (en) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | The anti-antibody of PD 1 and its application |
CA3080200A1 (en) | 2013-09-13 | 2015-03-19 | Beigene Switzerland Gmbh | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
CA2932966C (en) | 2013-12-12 | 2022-03-22 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Pd-1 antibody, antigen-binding fragment thereof, and medical use thereof |
TWI681969B (en) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
JOP20200094A1 (en) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-1 and uses thereof |
WO2016005004A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
TWI595006B (en) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | Anti-pd-1 antibodies and methods of use thereof |
PE20231958A1 (en) | 2015-07-30 | 2023-12-06 | Macrogenics Inc | BINDING MOLECULES TO PD-1 AND METHODS OF USE THEREOF |
WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
EP3344656A1 (en) | 2015-09-01 | 2018-07-11 | Agenus Inc. | Anti-pd-1 antibodies and methods of use thereof |
EA201891093A1 (en) | 2015-11-03 | 2018-10-31 | Янссен Байотек, Инк. | ANTIBODIES SPECIFICALLY BINDING PD-1 AND THEIR APPLICATION |
WO2018033254A2 (en) * | 2016-08-19 | 2018-02-22 | Curevac Ag | Rna for cancer therapy |
JP6949131B2 (en) * | 2017-02-28 | 2021-10-13 | サノフイSanofi | Therapeutic RNA |
-
2020
- 2020-01-17 EP EP20705267.1A patent/EP3914355A1/en active Pending
- 2020-01-17 CN CN202080010292.0A patent/CN113507963A/en active Pending
- 2020-01-17 BR BR112021013965-6A patent/BR112021013965A2/en not_active Application Discontinuation
- 2020-01-17 WO PCT/US2020/014039 patent/WO2020154189A1/en unknown
- 2020-01-17 KR KR1020217026319A patent/KR20210118870A/en unknown
- 2020-01-17 AU AU2020210614A patent/AU2020210614A1/en not_active Abandoned
- 2020-01-17 JP JP2021541607A patent/JP2022518236A/en active Pending
- 2020-01-17 SG SG11202107396RA patent/SG11202107396RA/en unknown
- 2020-01-17 MX MX2021008605A patent/MX2021008605A/en unknown
- 2020-01-17 TW TW109101808A patent/TW202043274A/en unknown
- 2020-01-17 CA CA3126110A patent/CA3126110A1/en active Pending
-
2021
- 2021-07-06 IL IL284645A patent/IL284645A/en unknown
- 2021-07-20 US US17/380,251 patent/US20220288199A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response | |
Comes et al. | CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine | |
JP2021155442A (en) | Nant cancer vaccines | |
Lozupone et al. | Effect of human natural killer and γδ T cells on the growth of human autologous melanoma xenografts in SCID mice | |
Cappello et al. | LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice | |
Zhang et al. | Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors | |
Liu et al. | Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma | |
Arvedson et al. | Targeting solid tumors with bispecific T cell engager immune therapy | |
KR20190096936A (en) | Immune Modulation with TLR9 Agonists for Cancer Treatment | |
Sun et al. | The IL-1 family in tumorigenesis and antitumor immunity | |
Rui et al. | Cancer immunotherapies: advances and bottlenecks | |
CN113412334A (en) | Plasmid constructs for treating cancer and methods of use | |
US20230190803A1 (en) | Method of treatment of cancer or tumour | |
Liao et al. | The common costimulatory and coinhibitory signaling molecules in head and neck squamous cell carcinoma | |
Bertol et al. | Lenvatinib plus anti-PD-1 combination therapy for advanced cancers: defining mechanisms of resistance in an inducible transgenic model of thyroid cancer | |
EP4149631A1 (en) | Method of treatment of cancer or tumour | |
Wang et al. | Improving the therapeutic index in adoptive cell therapy: key factors that impact efficacy | |
JPWO2020154189A5 (en) | ||
Bai et al. | Development of immunotherapy strategies targeting tumor microenvironment is fiercely ongoing | |
Wang et al. | Characteristics of tumor microenvironment and novel immunotherapeutic strategies for non-small cell lung cancer | |
Ueyama et al. | Immunotherapy Targeting CCR8+ Regulatory T Cells Induces Antitumor Effects via Dramatic Changes to the Intratumor CD8+ T Cell Profile | |
Yuan et al. | Immunotherapies catering to the unmet medical need of cold colorectal cancer | |
JP2020536049A (en) | Aldoxorubicin combination treatment and method | |
Wong et al. | Future of immunotherapy in pancreas cancer and the trials, tribulations and successes thus far | |
KR20220068272A (en) | Hank cetuximab combinations and methods |